147 related articles for article (PubMed ID: 35997004)
1. Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma.
Yang D; Xu F; Li Y; Lai X; Xian B; Yu P; Chen R; Li Z; Ma D
Thorac Cancer; 2022 Oct; 13(19):2786-2791. PubMed ID: 35997004
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet BY; Esfahani MS; Moding EJ; Hamilton EG; Chabon JJ; Rizvi H; Steen CB; Chaudhuri AA; Liu CL; Hui AB; Almanza D; Stehr H; Gojenola L; Bonilla RF; Jin MC; Jeon YJ; Tseng D; Liu C; Merghoub T; Neal JW; Wakelee HA; Padda SK; Ramchandran KJ; Das M; Plodkowski AJ; Yoo C; Chen EL; Ko RB; Newman AM; Hellmann MD; Alizadeh AA; Diehn M
Cell; 2020 Oct; 183(2):363-376.e13. PubMed ID: 33007267
[TBL] [Abstract][Full Text] [Related]
3. Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma.
Morimoto Y; Matsuda S; Kawakubo H; Nakamura K; Kobayashi R; Hisaoka K; Okui J; Takeuchi M; Aimono E; Fukuda K; Nakamura R; Saya H; Nishihara H; Kitagawa Y
Ann Surg Oncol; 2023 Jun; 30(6):3747-3756. PubMed ID: 36788188
[TBL] [Abstract][Full Text] [Related]
4. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Tolmeijer SH; van Wilpe S; Geerlings MJ; von Rhein D; Smilde TJ; Kloots ISH; Westdorp H; Coskuntürk M; Oving IM; van Ipenburg JA; van der Heijden AG; Hofste T; Weiss MM; Schalken JA; Gerritsen WR; Ligtenberg MJL; Mehra N
Eur Urol Oncol; 2024 Apr; 7(2):282-291. PubMed ID: 37673768
[TBL] [Abstract][Full Text] [Related]
5. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
[TBL] [Abstract][Full Text] [Related]
7. Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report.
Yao Y; Liu Z; Li Q; Cao B; Wang M
Thorac Cancer; 2022 Feb; 13(3):497-501. PubMed ID: 35014762
[TBL] [Abstract][Full Text] [Related]
8. Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites.
Guo JC; Lin CY; Lin CC; Huang TC; Lien MY; Lu LC; Kuo HY; Hsu CH
Oncology; 2021; 99(10):652-658. PubMed ID: 34340231
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
10. Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients.
Li H; Li B; Wang X; Zhang H; Wang C; Fan B; Wang L
Nutrition; 2024 Aug; 124():112462. PubMed ID: 38663128
[TBL] [Abstract][Full Text] [Related]
11. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
12. Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Kim JH; Ahn B; Hong SM; Jung HY; Kim DH; Choi KD; Ahn JY; Lee JH; Na HK; Kim JH; Kim YH; Kim HR; Lee HJ; Kim SB; Park SR
Cancer Res Treat; 2022 Apr; 54(2):505-516. PubMed ID: 34176250
[TBL] [Abstract][Full Text] [Related]
13. Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer.
Fujisawa R; Iwaya T; Endo F; Idogawa M; Sasaki N; Hiraki H; Tange S; Hirano T; Koizumi Y; Abe M; Takahashi T; Yaegashi M; Akiyama Y; Masuda M; Sasaki A; Takahashi F; Sasaki Y; Tokino T; Nishizuka SS
Carcinogenesis; 2021 Oct; 42(10):1239-1249. PubMed ID: 34559206
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J; Li Y; Fan Q; Shu Y; Yang L; Cui T; Gu K; Tao M; Wang X; Cui C; Xu N; Xiao J; Gao Q; Liu Y; Zhang T; Bai Y; Li W; Zhang Y; Dai G; Ma D; Zhang J; Bai C; Huang Y; Liao W; Wu L; Chen X; Yang Y; Wang J; Ji S; Zhou H; Wang Y; Ma Z; Wang Y; Peng B; Sun J; Mancao C
Nat Commun; 2022 Feb; 13(1):857. PubMed ID: 35165274
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma.
Luo H; Li H; Hu Z; Wu H; Liu C; Li Y; Zhang X; Lin P; Hou Q; Ding G; Wang Y; Li S; Wei D; Qiu F; Li Y; Wu S
Biochem Biophys Res Commun; 2016 Mar; 471(4):596-602. PubMed ID: 26876573
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
19. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
[TBL] [Abstract][Full Text] [Related]
20. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
